|
Journal of Medicine and Biomedical Research
College of Medical Sciences, University of Benin
ISSN: 1596-6941
Vol. 3, Num. 1, 2004, pp. 5-6
|
Untitled Document
Journal of Medicine and Biomedical Research, Vol. 3, No. 1, June 2004,
pp. 5-6
Editorial
Prevention of malaria in pregnancy: an important public health
challenge
FE Okonofua*
* Editor & Professor, Department of Obstetrics and Gynecology,
College of Medical Sciences, University of Benin, Benin City, Nigeria
Code Number: jm04001
Although malaria affects men and women of all ages in highly
endemic areas, it exerts its most deleterious clinical effects in adults during
pregnancy. Of all the known types of malaria parasites, Plasmodium falciparium is
the most common parasite responsible for disease and clinical manifestations
in pregnant women. During pregnancy, there is a significant reduction in cell-mediated
as well as humoral immunity to malaria, result-ing in more severe clinical
effects in pregnant than non-pregnant women. Young primigravid women are at
greater risk of malaria as compared to older women of high parity.
There is now substantial evidence suggesting that malaria
is responsible for a large number of complications in pregnancy including moderate
to severe anemia, low birth weight babies, premature onset of labour and increased
risk of stillbirths.1 Malaria is now accepted to be the principal
cause of the high prevalence of anaemia in pregnant women in holo-endemic areas,
contributing significantly to high rates of perinatal and maternal mortality
in these areas.2 In view of these effects of malaria in pregnancy,
the prevention of malaria has been accepted by the World Health Organization
to be an important public health measure for improving perinatal and maternal
health in developing countries.
Of the known methods of malaria prevention, chemoprophylaxis
is the most practical and most cost-effective in pregnant
women. Indeed, the WHO has
identified chemoprophylaxis as key to preventing malaria in pregnant women and
reducing the scale of its adverse clinical consequences. Other measures such
as
insecticide-treated bed nets and vector control have not
proven to be as effective as chemoprophylaxis
largely because malaria in pregnant women appears to be a recrudescence of previously
dormant infections rather than being new infections.
Despite the apparent simplicity of chemoprophylaxis, there
has been considerable difficulty in applying its principles as a public health
measure to prevent malaria in pregnant women. The first problem has been that
of drug efficacy and effectiveness. For many years, no single drug or combinations
of drugs could be identified as the indisputable leader in terms of efficacy
and effectiveness in preventing malaria in pregnancy. Several drug regimens
were used in the past including cholorquine, pyrimethamine, proguanil and mefloquine,1 but
none was consistently effective due to the emergence of drug resistance and
other related factors. More recently, based on trials conducted in East Africa,1,3,4 the
WHO has recommended the use of intermittent preventive treatment with suphadoxine-pyrimethamine
(IPT) with two or three-dose treatment regimens once during the second trimester
and once or twice during the third trimester.4 This regimen has
proven to be more effective than traditional regimens and
has been adopted by a number of
countries including Nigeria.5
Having identified this reasonably effective chemoprophylactic
regimen, the second challenge is to ensure that high-risk pregnant women have
access to the drug for the prevention of malaria. Access is limited by many
factors including low providers' awareness of the regimen, poor health-seeking
behaviour of pregnant women who tend not to receive antenatal care and poor
availability of drugs. Of these, the first two may be the most important reasons
for poor access to IPT in many developing countries. There is evidence that
a large number of health professionals in these countries are still not familiar
with IPT, while only a small proportion of pregnant women in malaria endemic
areas receive evidence-based antenatal care. Among pregnant women receiving
antenatal care, only a few are given anti-malarial chemoprophylaxis, while
the majorities are often given antimalarial regimens of doubtful efficacy.
Indeed, IPT is still relatively unknown in many clinical settings in regions
with high prevalence rates of malaria in pregnant women.
Thus, as part of public health measures to reduce the impact
of malaria in pregnancy, there is a need to build the capacity of health providers
on IPT, disseminate related information to providers and the general public,
and to integrate the method into clinical practices at all levels of the health
care system. More specifically, women need to be made aware of the method,
and they need to be encouraged to seek facility-based methods of antenatal
care rather than home-based care to increase their chances of receiving IPT
in pregnancy. Also, in view of the apparent simplicity of IPT, it may be possible
in future to explore its use by low cadre health workers such as community
health extension workers and traditional birth attendants. IPT can also be
included as a major component of home-based antenatal care offered by midwives
to women who
would not attend facility-based
antenatal care.
In conclusion, the prevention of malaria is an important public
health measure for improving maternal and perinatal health in developing countries.
Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine is
the current "best practice" for preventing malaria in pregnant women
in endemic countries. However, more research is needed to determine the effectiveness
and relative effectiveness of the method in various clinical settings, as well
as research to determine how best to integrate the method into existing levels
of the health care delivery system. Clearly, the prevention of malaria is one
of the most important interventions for promoting safe motherhood in tropical
and sub-tropical climates at the present time, and warrants more active promotion.
References
- Somwumi A. Malaria in pregnancy. In: Okonofua FE and Odunsi
K (Eds.). Contemporary Obstetrics and Gynecology for Developing Countries. Benin
City: Women's Health and Action Research Centre, 2003, pp 502_513.
- Ogunbode O. Anaemia in pregnancy. In: Okonofua FE and Odunsi
K (Eds.). Contemporary Obstetrics and Gynecology for Developing Countries. Benin
City: Women's Health and Action Research Centre, 2003, pp 514_529.
- Verhoeff FH, Brabin BJ, Hart CA, Chimsuku L, Kazembe P,
Russell WB and Broadhead RL. An evaluation of the effects of intermittent
sulfadoxine-pyrimethamine treatment in pregnancy on the parasite clearance
and risk of low birth weight
in rural Malawi. Ann Trop Parasitol 1998; 92: 141_150.
- World Health Organization. The use of antimalarial drugs.
Report of a WHO informal consultation. Geneva WHO/CDS/RBM/201.33
- Federal Ministry of Health, Nigeria. Intermittent preventive
treatment of malaria in Nigeria _ strategy for preventing malaria in pregnancy.
Report of a national consultation, May 2004.
© CMS UNIBEN JMBR
|